AMP-410 / Ampersand Biomedicines - LARVOL DELTA

AMP-410: A VEGF-dependent conditional 4-1BB agonist drives localized antitumor immunity with high therapeutic index across multiple tumor types (AACR-IO 2026) - "The conditional 4-1BB agonist AMP-410 elicits potent, localized antitumor immunity by activating 4-1BB selectively within VEGF-rich tumors. This mechanism maximizes tumor-specific immune activation and tolerability, achieving durable efficacy with a high therapeutic index. These findings support the advancement of AMP-410 for clinical evaluation as a first-in-class tumor-localized 4-1BB immunotherapy."

Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD34 • CD8 • IFNG • PD-1

Ampersand Biomedicines Presents Preclinical Data on AMP-410, a Novel Anti-VEGF/4-1BB Bifunctional AND-Body Therapeutic, at AACR 2025 (GlobeNewswire) - "Ampersand Biomedicines...announced preclinical data for one of its lead development candidates, AMP-410, a novel potential first-in-class bifunctional anti-VEGF/4-1BB AND-Body therapeutic....AMP-410 was evaluated in multiple preclinical models of hard-to-treat cancers, including melanoma, colorectal, and lung cancer. Findings show that AMP-410 induced more durable anti-tumor immunity compared to four other classes of clinical immunotherapies. Notably, AMP-410 showed initial promising monotherapy efficacy compared to an anti-VEGF/PD-1 bispecific antibody in a non-small cell lung cancer (NSCLC) model, demonstrating its potential to treat tumors resistant to checkpoint inhibitors. AMP-410 monotherapy achieved 90% tumor-free survival in colorectal cancer and extended survival in melanoma models; when combined with anti-PD-1, it drove 100% tumor-free survival in colorectal cancer and further extended survival in melanoma."

Preclinical • Colorectal Cancer • Melanoma • Non Small Cell Lung Cancer

Ampersand Biomedicines Raises Series B Financing and Highlights Pipeline Advancements (GlobeNewswire) - "Ampersand Biomedicines...today announced it has secured $65 million in Series B funding from investors including Ampersand’s founder, Flagship Pioneering, Eli Lilly & Company, and several additional new investors. In addition, the company announced the advancement of two lead programs and a second discovery partnership in obesity...The funding will also drive the acceleration of Ampersand’s initial pipeline of impactful programs, including one in immuno-inflammation and another in immuno-oncology, both of which are planned to enter IND-enabling studies in 2025."

Financing • Preclinical • Immunology • Obesity • Oncology